MODERN METHODS OF DIAGNOSTICS OF HEMOLYTIC DISEASE OF YOUNG CHILDREN
Keywords:
Symptoms, Diagnosis, Prevention, TreatmentAbstract
Hemolytic disease of the newborn is a condition in which red blood cells are destroyed or destroyed by the mother's antibodies. Hemolysis is the destruction of red blood cells. This disease can occur when there is an incompatibility (incompatibility) between the blood of the mother and the blood of the fetus. The diagnosis is based on the results of a blood test for the mother and, in some cases, for the father. Sometimes immunoglobulin is administered to the mother during pregnancy to prevent this disease in newborns. Treatment may include blood transfusions to the fetus before birth and to the newborn after birth. Red blood cells contain hemoglobin, a protein that gives the blood its red color and carries oxygen from the lungs to all tissues of the body. Oxygen is used by cells to help the body produce the energy it needs from food, while carbon dioxide is released as a waste product. Red blood cells return carbon dioxide from the tissues to the lungs. When the red blood cell count is too low, the blood carries less oxygen, causing fatigue and weakness. Hemolytic disease of the newborn can lead to an increase in the level of bilirubin in the blood (hyperbilirubinemia), a low level of red blood cells (see Anemia in newborns), and in rare cases, in the most severe forms, death. Bilirubin is a yellow pigment produced during the normal breakdown of red blood cells.
References
1. Rustamovich, A. I., Negmatovich, T. K., & Fazliddinovich, S. D. (2022). БОЛАЛИКДАН БОШ МИЯ ФАЛАЖИ ФОНИДА РИНОСИНУСИТИ БОР БЕМОРЛАРДА БУРУН БЎШЛИҒИ МУКОЦИЛИАР ТРАНСПОРТИ НАЗОРАТИ ТЎҒРИСИДАГИ ЗАМОНАВИЙ ҚАРАШЛАР (адабиётлар шарҳи). JOURNAL OF BIOMEDICINE AND PRACTICE, 7(2).
2. Абдурахмонов, И. Р. & Шамсиев, Д. Ф. (2021). Эффективность применения местной антибиотикотерапии в лечении параназального синусита у детей с церебральным параличем. In НАУКА И ОБРАЗОВАНИЕ: СОХРАНЯЯ ПРОШЛОЕ, СОЗДАЁМ БУДУЩЕЕ (pp. 336-338).
3. Абдураҳмонов, И. Р., & Шамсиев, Д. Ф. (2021). Болаликдан бош мия фалажи билан болалардаги ўткир ва сурункали параназал синуситларни даволашда мукорегуляр дори воситасини самарадорлигини ўрганиш. T [a_XW [i [S US S_S^[ǜe YfcS^, 58.
4. Siddikov, O., Daminova, L., Abdurakhmonov, I., Nuralieva, R., & Khaydarov, M. OPTIMIZATION OF THE USE OF ANTIBACTERIAL DRUGS DURING THE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Turkish Journal of Physiotherapy and Rehabilitation, 32, 2.
5. Тураев, Х. Н. (2021). Абдурахмонов Илхом Рустамович Влияние будесонида на качество жизни пациентов с бронхиальным обструктивным синдромом. Вопросы науки и образования, 7, 132.
6. Абдурахманов, И., Шамсиев, Д., & Олимжонова, Ф. (2021). Изучение эффективности мукорегулярных препаратов в лечении острого и хронического параназального синусита при детском церебральном параличе. Журнал стоматологии и краниофациальных исследований, 2(2), 18-21.
7. Абдураҳмонов, И. Р., & Шамсиев, Д. Ф. (2023). БОШ МИЯ ФАЛАЖИ ФОНИДАГИ ПАРАНАЗАЛ СИНУСИТЛАРНИ ДАВОЛАШДА ЎЗИГА ХОС ЁНДАШИШ. MedUnion, 2(1), 14-26.
8. Орипов, Р. А., Абдурахмонов, И. Р., Ахмедов, Ш. К., & Тураев, Х. Н. (2021). ОСОБЕННОСТИ ПРИМЕНЕНИЕ АНТИОКСИДАНТНЫХ ПРЕПАРАТОВ В ЛЕЧЕНИИ НЕЙРОДЕРМИТА.
9. Ахмедов, Ш. К., Тураев, Х. Н., Абдурахмонов, И. Р., & Орипов, Р. А. (2021). НЕКОТОРЫЕ ОСОБЕННОСТИ ТАКТИКИ ПРОДУКТИВНОГО ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ КРАПИВНИЦЫ.
10. Абдурахмонов, И. Р. (2021). Исследование мукоцилиарной транспортной функции слизистой оболочки полости носа у больных с параназальным синуситом на фоне детского церебрального паралича. In Актуальные аспекты медицинской деятельности (pp. 256-259).
11. Абдурахмонов, И. Р., & Тураев, Х. Н. (2022). ОПЫТ ПРИМЕНЕНИЯ СИНУПРЕТА С АНТИБАКТЕРИАЛЬНЫМИ ПРЕПАРАТАМИ В КОМПЛЕКСНОЙ ТЕРАПИИ РИНОСИНУСИТОВ У БОЛЬНЫХ ДЕТСКИМ ЦЕРЕБРАЛЬНЫМ ПАРАЛИЧОМ. Достижения науки и образования, (2 (82)), 88-92.
12. Abdurakhmanov, I., & Shernazarov, F. (2023). SPECIFIC ASPECTS OF TREATMENT OF CHRONIC RHINOSINUSITIS IN CHILDREN. Science and innovation, 2(D10), 164-168.
13. Andryev S. et al. Experience with the use of memantine in the treatment of cognitive disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 282-288.
14. Antsiborov S. et al. Association of dopaminergic receptors of peripheral blood lymphocytes with a risk of developing antipsychotic extrapyramidal diseases //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 29-35.
15. Asanova R. et al. Features of the treatment of patients with mental disorders and cardiovascular pathology //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 545-550.
16. Begbudiyev M. et al. Integration of psychiatric care into primary care //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 551-557.
17. Bo’Riyev B. et al. Features of clinical and psychopathological examination of young children //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 558-563.
18. Borisova Y. et al. Concomitant mental disorders and social functioning of adults with high-functioning autism/asperger syndrome //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 36-41.
19. Ivanovich U. A. et al. Efficacy and tolerance of pharmacotherapy with antidepressants in non-psychotic depressions in combination with chronic brain ischemia //Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 409-414.
20. Nikolaevich R. A. et al. Comparative effectiveness of treatment of somatoform diseases in psychotherapeutic practice //Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 898-903.
21. Novikov A. et al. Alcohol dependence and manifestation of autoagressive behavior in patients of different types //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 413-419.
22. Pachulia Y. et al. Assessment of the effect of psychopathic disorders on the dynamics of withdrawal syndrome in synthetic cannabinoid addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 240-244.
23. Pachulia Y. et al. Neurobiological indicators of clinical status and prognosis of therapeutic response in patients with paroxysmal schizophrenia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 385-391.
24. Pogosov A. et al. Multidisciplinary approach to the rehabilitation of patients with somatized personality development //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 245-251.
25. Pogosov A. et al. Rational choice of pharmacotherapy for senile dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 230-235.
26. Pogosov S. et al. Gnostic disorders and their compensation in neuropsychological syndrome of vascular cognitive disorders in old age //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 258-264.
27. Pogosov S. et al. Prevention of adolescent drug abuse and prevention of yatrogenia during prophylaxis //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 392-397.
28. Pogosov S. et al. Psychogenetic properties of drug patients as risk factors for the formation of addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 186-191.
29. Prostyakova N. et al. Changes in the postpsychotic period after acute polymorphic disorder //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 356-360.
30. Prostyakova N. et al. Issues of professional ethics in the treatment and management of patients with late dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 158-165.
31. Prostyakova N. et al. Sadness and loss reactions as a risk of forming a relationship together //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 252-257.
32. Prostyakova N. et al. Strategy for early diagnosis with cardiovascular diseaseisomatized mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 166-172.
33. Rotanov A. et al. Comparative effectiveness of treatment of somatoform diseases in psychotherapeutic practice //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 267-272.
34. Rotanov A. et al. Diagnosis of depressive and suicidal spectrum disorders in students of a secondary special education institution //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 309-315.
35. Rotanov A. et al. Elderly epilepsy: neurophysiological aspects of non-psychotic mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 192-197.
36. Rotanov A. et al. Social, socio-cultural and behavioral risk factors for the spread of hiv infection //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 49-55.
37. Rotanov A. et al. Suicide and epidemiology and risk factors in oncological diseases //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 398-403.
38. Sedenkov V. et al. Clinical and socio-demographic characteristics of elderly patients with suicide attempts //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 273-277.
39. Sedenkov V. et al. Modern methods of diagnosing depressive disorders in neurotic and affective disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 361-366.
40. Sedenkova M. et al. Basic principles of organizing gerontopsychiatric assistance and their advantages //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 63-69.
41. Sedenkova M. et al. Features of primary and secondary cognitive functions characteristic of dementia with delirium //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 56-62.
42. Sedenkova M. et al. The possibility of predicting the time of formation and development of alcohol dependence: the role of genetic risk, family weight and its level //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 173-178.
43. Shamilov V. et al. Disorders of decision-making in the case of depression: clinical evaluation and correlation with eeg indicators //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 198-204.
44. Solovyova Y. et al. Protective-adaptive complexes with codependency //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 70-75.
45. Solovyova Y. et al. Suicide prevention in adolescents with mental disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 303-308.
46. Solovyova Y. et al. The relevance of psychotic disorders in the acute period of a stroke //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 212-217.
47. Spirkina M. et al. Integrated approach to correcting neurocognitive defects in schizophrenia //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 76-81.
